Naringin & TRT: Managing Hematocrit for Cardiovascular Health

Men with total testosterone below 300 ng/dL have 2.4 times higher cardiovascular mortality compared to men with levels above 600 ng/dL, according to a 2018 study in the Journal of Clinical Endocrinology & Metabolism. Testosterone Replacement Therapy (TRT) offers life-changing benefits for men with symptomatic hypogonadism, ranging from improved energy and libido to enhanced bone mineral density and mood stability. However, like any powerful therapeutic intervention, TRT requires careful management of potential side effects. One common and significant concern is erythrocytosis, characterized by an elevated red blood cell count, hematocrit, and hemoglobin.

Last Updated: OCTOBER 2023

Understanding Erythrocytosis on TRT

Erythrocytosis, often interchangeably referred to as polycythemia (though polycythemia vera is a distinct, primary bone marrow disorder), is a common adverse event of TRT. Hematocrit, the percentage of red blood cells in your total blood volume, typically ranges from 40% to 52% in healthy adult males. On TRT, a hematocrit level consistently above 52% or 54% warrants attention and intervention due to increased risk of thrombotic events such as stroke, heart attack, or deep vein thrombosis.

Testosterone stimulates erythropoiesis, the production of red blood cells, primarily through increasing renal erythropoietin (EPO) synthesis. This effect is dose-dependent and can be influenced by the type and frequency of testosterone administration. Injectable testosterone esters like testosterone cypionate or enanthate, commonly prescribed at dosages such as 100–200mg per week, tend to cause higher peaks and troughs, which can sometimes lead to more pronounced erythrocytosis compared to daily topical applications.

Factors exacerbating erythrocytosis on TRT include:

• Higher TRT doses: More testosterone often means more erythropoietic stimulation.
• Infrequent injections: Longer intervals between injections (e.g., every 2 weeks) can lead to higher peak testosterone levels, driving red blood cell production more aggressively. Daily or twice-weekly injections of testosterone cypionate (e.g., 50mg twice weekly, totaling 100mg/week) tend to stabilize levels and may reduce erythrocytosis compared to less frequent dosing.
• Sleep apnea: Intermittent hypoxia due to untreated sleep apnea stimulates natural EPO production. This can compound the effect of exogenous testosterone.
• Dehydration: This can falsely elevate hematocrit on lab tests. Proper hydration before blood draws is crucial for accurate readings.
• Smoking: Chronic hypoxia from smoking also stimulates erythropoiesis.

The goal of TRT is to alleviate symptoms of hypogonadism and restore total testosterone to an optimal range, typically 600-900 ng/dL, and free testosterone to 15-25 pg/mL, while ensuring estrogen (E2) is maintained between 20-40 pg/mL on TRT. This range is far removed from the outdated lower bound of 264 ng/dL, which was calibrated from studies including sick and elderly men in the 1970s and does not represent a healthy optimal baseline. Managing erythrocytosis is part of this broader strategy for safe and effective hormone optimization.

Standard Management of Elevated Hematocrit

When hematocrit consistently rises above 52%, or even reaches 50-52% with underlying risk factors, proactive management is essential.

Dose Adjustment and Frequency

• Lowering the dose: Reducing the weekly testosterone cypionate dose from, for example, 150mg to 100mg can often mitigate the erythrocytosis.
• Increasing injection frequency: Shifting from weekly injections to twice-weekly (e.g., 100mg/week split into 50mg twice weekly) or even daily subcutaneous injections can create more stable testosterone levels and may reduce the pulsatile stimulation of EPO.

Phlebotomy

Therapeutic phlebotomy, or blood donation, is the most direct and effective method to rapidly reduce hematocrit. This involves removing 450-500mL of blood, similar to a standard blood donation. The frequency depends on individual response and hematocrit levels. Many TRT users donate blood every 8-12 weeks to manage their hematocrit, often maintaining it below 50%. Regular phlebotomy also helps manage iron stores, which can become elevated on TRT due to increased red blood cell turnover.

Lifestyle Interventions

• Hydration: Maintaining consistent hydration is fundamental. Aim for 2-3 liters of water daily.
• Addressing sleep apnea: If sleep apnea is diagnosed, treatment (e.g., CPAP) can significantly reduce EPO drive.
• Smoking cessation: Quitting smoking improves overall cardiovascular health and reduces chronic hypoxia.

Naringin: A Natural Approach to Hematocrit Control?

Naringin is a flavonoid glycoside found abundantly in grapefruit and other citrus fruits. It is responsible for the bitter taste of grapefruit. In recent years, naringin has garnered interest for its diverse biological activities, including antioxidant, anti-inflammatory, and anti-cancer properties. Emerging research suggests it may also play a role in modulating erythropoiesis and iron metabolism, offering a potential, albeit unproven for clinical TRT use, natural adjunct for managing elevated hematocrit.

Proposed Mechanisms of Action

The exact mechanisms by which naringin might influence hematocrit are complex and are largely derived from in vitro and animal studies, not direct clinical trials in TRT patients. However, current research points to a few key areas:

1. Iron Metabolism Regulation: A study published in the Journal of Nutritional Biochemistry in 2021, “Naringin ameliorates high-fat diet-induced erythroid hyperplasia and iron overload through inhibiting intestinal iron absorption,” highlighted naringin’s potential role in regulating iron. The study, conducted in mice, suggested that naringin could reduce intestinal iron absorption and ameliorate iron overload, thereby indirectly impacting erythropoiesis. Given that iron is a critical component of hemoglobin synthesis, modulating its absorption could in theory dampen excessive red blood cell production.
2. Modulation of Erythropoietin Signaling: Some in vitro and animal models suggest naringin may influence pathways related to cellular proliferation and differentiation, including those involved in erythropoiesis. While direct evidence linking naringin to human EPO suppression in the context of TRT is lacking, it remains an area of ongoing investigation.
3. Anti-inflammatory Effects: Chronic low-grade inflammation can sometimes influence